HAVCR2 and neoplasm: This antitumor effect is driven by direct TIM-3 inhibition in tumor cells, coordinated immune cell actions, and the secretion of chemokines/cytokines that promote a proinflammatory microenvironment, enhancing the antitumor immune response (Ausejo-Mauleon et al., 2023; Hu Y. et al., 2024; Lee and Lathia, 2023).